Skip to main content

Table 2 Model parameters used to fit the incidence/prevalence of HCV patients observed in the Dat’AIDS cohort between 2012 and 2016 and for the different projections

From: Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination

Parameter

Symbol

Point value

Unit

References

Death rate

μ

1.4%

per year

Dat’AIDS

Infection rate of HIV (in each risk group j)

θj

see Reference

[19, 20]

Proportion of HCV spontaneous clearance

γ

12.6%

Dat’AIDS

Mean duration of acute infection

1/Ψ

180

days

[9]

Infection rate of HCV among HIV patients in each risk group j

βj

estimated

Dat’AIDS

Treatment coverage rate

τ

(30–90)

per year

Average treatment duration

1/ω

12 (since 2015) and 24 (before 2015)

weeks

DAA treatment SVR12 rate

α

95%

Dat’AIDS

Re-infection rate of HCV among HIV patients after SVR12 or spontaneous clearance in each risk group j

δj

see Table 1

per year

Dat’AIDS

  1. DAA direct-acting antivirals, HCV hepatitis C virus, HIV human immunodeficiency virus, SVR sustained virological response